New Treatment Options for Pulmonary Arterial Hypertension — The First Selective IP-receptor Agonist Selexipag

Cardiovascular Therapy and Prevention (Russian Federation) - Russian Federation
doi 10.15829/1728-8800-2019-6-80-87
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Silicea - Poligraf, LLC